Dana Brinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dana Brinson has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Golnaz Karoubi
Latner Thoracic Research Laboratories, University Health Network, Toronto, ON M5G 1L7, Canada
2 shared publications - Cindy Lei
Latner Thoracic Research Laboratories, University Health Network, Toronto, Ontario, Canada, uhn.ca
1 shared publication - Jason Say
Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto General Hospital, University of Toronto, 101 College Street, Toronto, Ontario, Canada, M5G 0A3
1 shared publication - Muyang Zhou
Latner Thoracic Research Laboratories, University Health Network, Toronto, Ontario, Canada, uhn.ca
1 shared publication - Shiyuan Bian
Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King's College Circle, Toronto, Ontario, Canada M5S 1A8; Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto General Hospital, University of Toronto, 101 College Street, Toronto, Ontario, Canada, M5G 0A3
1 shared publication
Latest Publications
- 6 December 2025
- Published by Elsevier in Trends in Biotechnology
- Vol. 44 (7) , 1892-1907
Advances in lung biomimetic systems: exploring biophysical cues in lung regenerative medicine
- 6 December 2025
- Published by Elsevier in Trends in Biotechnology
- Vol. 44 (7) , 1892-1907
Advances in lung biomimetic systems: exploring biophysical cues in lung regenerative medicine
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 2025 (1)
Recent Advancements in the Generation and Application of Therapeutic Cell Populations for Lung Epithelial Repair
Chronic respiratory diseases are a major global health concern. Lung epithelial dysfunction is a common underlying feature of many such conditions; hence, reconstructing the diseased epithelium with functional epithelial cells is a promising therapeutic approach. There are various endogenous stem cell and progenitor populations in the lung epithelium that can be utilized for transplantation. Additionally, pluripotent stem cells (PSCs) have emerged as a valuable source for generating therapeutic cells due to their capacity for indefinite self‐renewal and the availability of directed differentiation protocols to transform them into lung progenitors or mature lung epithelial cells. This review discusses the endogenous stem cell and progenitor populations of the lung epithelium, recent advances in developing directed differentiation protocols to generate these cells, and the application of both endogenous and PSC‐derived lung epithelial cells for disease modeling in vitro and as cell therapies in vivo. It provides valuable insights into the current progress of regenerative medicine within the respiratory field and highlights areas that require further research.
- 1 January 2025
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 2025 (1)
Open AccessRecent Advancements in the Generation and Application of Therapeutic Cell Populations for Lung Epithelial Repair
Chronic respiratory diseases are a major global health concern. Lung epithelial dysfunction is a common underlying feature of many such conditions; hence, reconstructing the diseased epithelium with functional epithelial cells is a promising therapeutic approach. There are various endogenous stem cell and progenitor populations in the lung epithelium that can be utilized for transplantation. Additionally, pluripotent stem cells (PSCs) have emerged as a valuable source for generating therapeutic cells due to their capacity for indefinite self‐renewal and the availability of directed differentiation protocols to transform them into lung progenitors or mature lung epithelial cells. This review discusses the endogenous stem cell and progenitor populations of the lung epithelium, recent advances in developing directed differentiation protocols to generate these cells, and the application of both endogenous and PSC‐derived lung epithelial cells for disease modeling in vitro and as cell therapies in vivo. It provides valuable insights into the current progress of regenerative medicine within the respiratory field and highlights areas that require further research.